On a disclosed basis, annual revenue rose from KRW 80 billion in 2022 to KRW 81.4 billion in 2023 (up 1.7% year on year), the peak year. It then fell 10.3% to KRW 73 billion in 2024 and 14.4% to KRW 62.5 billion in 2025, a second consecutive annual decline.
Among 2022 to 2025, 2023 was the largest year and 2025 the smallest. Operating profit rose from KRW 14.3 billion in 2022 to KRW 18 billion in 2023 (up 25.8%), then fell 49.3% to KRW 9.14 billion in 2024 and 24.4% to KRW 6.91 billion in 2025.
Operating margin declined from 17.9% in 2022 and 22.2% in 2023 to 12.5% in 2024 and 11.1% in 2025. Since 2024, operating profit has fallen faster than revenue, showing clear margin pressure.
Net income attributable to controlling shareholders moved from KRW 11.8 billion in 2022 to a net loss of KRW 4.92 billion in 2023, a swing into loss. The 2023 loss came despite positive operating profit, which points to a large effect from non-operating items.
The company returned to a profit of KRW 3 billion in 2024 and rose to KRW 6.51 billion in 2025, up 117.4%. Net income including non-controlling interests was also KRW 6.51 billion in 2025.
Operating cash flow was KRW 5.91 billion in 2022, negative KRW 2 billion in 2023, KRW 4.87 billion in 2024 and KRW 13.1 billion in 2025, the highest of the four years.
Year-end 2025 total equity of KRW 83.1 billion was entirely attributable to controlling shareholders, with total liabilities of KRW 11.2 billion and a debt ratio of 13.5%.
Quarterly revenue went from KRW 16.5 billion in the third quarter of 2025 and KRW 18 billion in the fourth quarter to a low of KRW 13.3 billion in the first quarter of 2026, down 25.9% from the prior quarter.
It then rose to KRW 17.6 billion in the second quarter (up 31.7%) and KRW 18.3 billion in the third quarter (up 11.2% year on year), a two-quarter run of growth.
Operating profit was KRW 1.18 billion in the first quarter of 2026, KRW 2.66 billion in the second and KRW 2.25 billion in the third, positive in each quarter.
Net income attributable to controlling shareholders, however, swung to a net loss of KRW 3.44 billion in the second quarter before returning to a profit of KRW 1.96 billion in the third.
Net income attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totaled KRW 1.54 billion. Pharm News cited the cost of sales ratio falling from 56.5% to 53.4% in the first half of 2026 as a driver of margin improvement.